Perhaps reading the NVCR Optune pivotal Phase 3 trial results in the high quality peer-reviewed journals.
NWBO has repeatedly stated the naive OS data was confounded which bias the results. The post hoc data dredged rGBM data is not going to be acceptable for an FDA approval as post hoc data dredging is useful for "exploaratory" findings but not for regulatory approval -- it is only 64 patients and was not even part of the original trial protocol.
Market Data 
Markets 
AI
